Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STUNNIN: SBRT ± short-term androgen deprivation for unfavorable intermediate/high-risk prostate cancer
2020-004195-17Phase 2Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- May 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of leuprolide, triptorelin and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: 3-year biochemical no evidence of disease (bNED) survival. Started May 2021; status: active.
02
Drugs
leuprolidetriptorelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-004195-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004195-17.